Population and data characteristics
In total 21 patients were included in the study, contributing to a total
of 97 PK samples (13 plasma samples and 84 DBS samples). Results from
three (3%) samples were excluded due to incorrect DBS sampling (1), and
missing dosing information (2). Ivacaftor-M6 concentration in 3 samples
(3%) was below the LLOQ and excluded. No samples were above the ULOQ.
Patient demographics and baseline characteristics are summarized in
table 1. All patients used tezacaftor-ivacaftor according to the dose
recommendation as stated in the product information. (3)